Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Si-Bone
SIBN · NASDAQ · Surgical & Medical Instruments & Apparatus
No open-market purchase by an insider of Si-Bone was filed in the last 90 days. The latest on record was on Oct 19, 2018.
How often do Si-Bone insiders buy and sell shares?
Since 2018, Si-Bone insiders reported 4 open-market purchases and 620 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2018.
Who is selling Si-Bone stock?
In the last 90 days, 4 insiders of Si-Bone (SIBN) reported 15 open-market sales worth $5.32M in total on SEC Form 4. The largest seller by value was Laura Francis, with $2.66M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade SIBN?
No trade in Si-Bone (SIBN) was disclosed by a member of Congress in the last 12 months.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$23.73−0.02 (−0.08%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
SIBN price and disclosed activity
+27.0% (+$5.05) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $18.68 on Nov 20, 2025 to $23.73 on Nov 20, 2026 (+27.0%). Disclosed in this range: 0 insider trades, 26 pre-arranged insider sales, 0 Congress trades, and 1 13F position change for 1 quarter ending in it.
$10$15$20$30$23.73
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 26 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Surgical & Medical Instruments & Apparatus company based in Santa Clara, Ca.
Last 12 months
+27.0%
S&P 500 +5.7% over the same dates
Market value
$1.04B
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 4.53M shares sold short (10.3% of shares outstanding), −3.8% vs the previous count, 6.8 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Latest results: quarter ending Sep 30, 2026
Revenue
$55.7M
+14.5% vs the same quarter a year earlier
Free cash flow, last 12 months
−$4.19M
This quarter −$427K, a year earlier −$620K
Net debt
$346K
Debt $35.7M, cash $35.3M, at Sep 30, 2026
Net income, last 12 months
−$13.7M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 2, 2026.
Insiders of Si-Bone reported 4 open-market purchases and 620 sales since 2018; purchases in 2018.
Year
Bought
Sold
2026
—
$5.32M15×15 trades
2025
—
$4.29M88×88 trades
2024
—
$2.62M76×76 trades
2023
—
$11.3M94×94 trades
2022
—
$1.46M75×75 trades
2021
—
$47.4M98×98 trades
2020
—
$37.5M76×76 trades
2019
—
$28.9M95×95 trades
2018
$13.9M4×4 trades
$116K3×3 trades
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Last 30 days
Written by software from the filings listed below · Nov 13, 2026
Insiders. In the 30 days to Nov 13, 2026, Si-Bone insiders filed 0 open-market purchases and 7 open-market sales, about $4.04M, in 6 filings by 4 people. Si-Bone on OQRO
3 more points, with the facts they come from, are in OQRO Pro.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
FDA, last 12 months
1 approval or clearance and 1 recall recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Fails to deliver: 84K shares (about $1.64M) were not delivered on time for settlement on Oct 19, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 36.6% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (29.0% on ATS, 7.6% with other brokers), below its 26-week average of 38.6%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: SIGMA X2 (11.7%), INTELLIGENT CROSS LLC (10.0%), UBS ATS (9.9%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Si-Bone filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 26 open-market sales (about $5.95M, in 13 filings, by 4 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 100 open-market sales (about $4.54M, in 33 filings). (Si-Bone on OQRO)
Funds and stakes. Fund 13F filings recorded in the 12 months show 0 new or larger positions and 1 smaller or closed position. A 13F is a snapshot of holdings at the end of a quarter. BROWN ADVISORY INC cut its SIBN stake below 5% (4.5%) (filed Nov 13, 2026).
Contracts, lobbying and filings. FDA records list 1 device clearance, 1 recall for Si-Bone between Nov 19, 2025 and Nov 19, 2026; the latest, on Sep 23, 2026: device clearance for iFuse Granite Onyx Implant System (510(k) clearance, traditional: Substantially Equivalent). FINRA short interest for SIBN on the settlement date of Oct 30, 2026 was 4,526,148 shares (-3.79% on the previous report), about 6.84 days of average volume.
Company reports, price and press. Si-Bone filed a Form 8-K on Nov 2, 2026 (Item 2.02) that OQRO classes as: reported its results. Si-Bone filed a Form 8-K on Sep 11, 2026 (Items 1.01, 2.03, 8.01) that OQRO classes as: signed an important agreement, and took on new debt or obligations (and 1 more item).
Who holds it. 168 funds reported a stake in Si-Bone in their 13F for Q2 2026. The largest by value: First Light Asset Management, LLC (16.9% of the value reported), BlackRock, Inc. (7.6% of the value reported), CADIAN CAPITAL MANAGEMENT, LP (7.0% of the value reported).
Risk factors in the annual report
Latest annual report filed Feb 24, 2026, compared with the one filed Feb 25, 2025. Read the filing
No longer listed (1 heading from the year before)
Inadequate funding for the FDA and other government agencies, or a work slowdown or stoppage at those agencies as part of a broader federal government shutdown, or comparable scenarios with foreign regulatory authorities, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
Legal proceedings (Item 3)
We may be subject to legal proceedings and claims in the ordinary course of business. We cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on us due to diversion of management time and attention as well as the financial costs related to resolving such disputes.
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Where the revenue comes from
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 24, 2026. Read the filing
By region
United States$191M95%
+21% on the year before ($158M)
International$9.85M4.9%
+12% on the year before ($8.76M)
Total revenue$201M+20%
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 6,000 words.
From “Overview”, in the company's words
We are a leader in developing innovative procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific innovation. As pioneers of minimally invasive treatment for sacroiliac joint dysfunction and degeneration, we developed a deep competency in addressing the challenges of low-density bone in the sacrum. With our additive manufacturing, or 3D-printing, experience developed in sacroiliac fusion, we have established a technology platform that now extends to meet critical unmet needs in thoracolumbar fixation and fusion and pelvic trauma.
What the section covers (33 headings)
Overview
Factors Affecting Results of Operations and Key Performance Indicators
Introduce Solutions Addressing New Markets
Expand Access to Solutions
Engage and Educate Physicians
Enhance Employee Experience and Engagement
Gain Operational Efficiency
Components of Results of Operations
Revenue
Cost of Goods Sold, Gross Profit, and Gross Margin
Operating Expenses
Sales and Marketing Expenses
Research and Development Expenses
General and Administrative Expenses
And 19 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Si-Bone filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 26 open-market sales (about $5.95M, in 13 filings, by 4 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 100 open-market sales (about $4.54M, in 33 filings).
The largest sale: Laura Francis, Chief Executive Officer, about $1.9M, filed Nov 6, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 0 new or larger positions and 1 smaller or closed position. A 13F is a snapshot of holdings at the end of a quarter.
BROWN ADVISORY INC cut its SIBN stake below 5% (4.5%) (filed Nov 13, 2026).
Contracts, lobbying and filings
FDA records list 1 device clearance, 1 recall for Si-Bone between Nov 19, 2025 and Nov 19, 2026; the latest, on Sep 23, 2026: device clearance for iFuse Granite Onyx Implant System (510(k) clearance, traditional: Substantially Equivalent).
FINRA short interest for SIBN on the settlement date of Oct 30, 2026 was 4,526,148 shares (-3.79% on the previous report), about 6.84 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Gilder Gagnon Howe & Co LLC (increased, 204,526 shares); Royce & Associates LP (increased, 24,006 shares); the largest that shrank: Susquehanna Portfolio Strategies, LLC (sold out); Freestone Grove Partners LP (sold out). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $7.45M for its principal executive officer, and an average of $2.53M for the other named executive officers.
Company reports, price and press
Si-Bone filed a Form 8-K on Nov 2, 2026 (Item 2.02) that OQRO classes as: reported its results.
Si-Bone filed a Form 8-K on Sep 11, 2026 (Items 1.01, 2.03, 8.01) that OQRO classes as: signed an important agreement, and took on new debt or obligations (and 1 more item).
Si-Bone filed a Form 8-K on Feb 23, 2026 (Items 1.01, 2.02, 5.02) that OQRO classes as: changed a top executive or board member, and signed an important agreement (and 1 more item).
The company's own opening sentence of that report reads: "On February 22, 2026, the Company appointed Anshul Maheshwari, the Company’s Chief Financial Officer, also as the Company’s Chief Operating Officer, effective February 22, 2026."
Press coverage listed by Finnhub: "SiBone Q3 Earnings Call Highlights" (Yahoo, Nov 3, 2026).
Press coverage listed by Finnhub: "SiBone Q2 Earnings Call Highlights" (Yahoo, Aug 3, 2026).
Press coverage listed by Finnhub: "SiBone Q1 Earnings Call Highlights" (Yahoo, May 12, 2026).
SIBN closed at $23.54 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $19.66 to $23.54, a change of +19.7%.
Who holds it
168 funds reported a stake in Si-Bone in their 13F for Q2 2026. The largest by value: First Light Asset Management, LLC (16.9% of the value reported), BlackRock, Inc. (7.6% of the value reported), CADIAN CAPITAL MANAGEMENT, LP (7.0% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Since Nov 18, 2025, SIBN is up 29.2% and the index fund is up 4.5%: 25 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much SIBN moves
A usual day
±1.6%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
4.6%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−12.6%Jan 12, 2026
Largest one-day rise
+19.7%May 12, 2026
Deepest fall of the year
−45.7%From the close of Jan 7, 2026 to May 11, 2026.
Days of 5% or more
20Out of 252 sessions, in either direction.
Beta 0.7(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).